Table 2. LAI-AP and OAP Utilization Profile.
| Delay between admission and first prescription of LAI-AP (months) (mean (s.d.)/median) | 6,0 (7,1)/3,2 | |
| Total exposure to LAI-AP (months) (mean (s.d.)) | 25,4 (7,6) | |
| Duration of first trial of LAI-AP (months) (mean (s.d.)) | 22,8 (10,0) | |
| Duration of first trial of OAPa (for OAP group, n = 275) (months) (mean (s.d.)) | 15,2 (14,9) | |
| Proportion of good adherence (>90% of adherence) to first trial of OAP group (%) | 57,2 | |
| Type of LAI-AP prescribed during 3-year follow-up, all trials combined (%) | – | |
| - Long-acting risperidone | 44,3 | |
| - Monthly paliperidone palmitate | 32,1 | |
| - Long-acting zuclopenthixol | 12,1 | |
| - Long-acting haloperidone | 7,9 | |
| - Long-acting flupenthixol | 2,1 | |
| - Long-acting aripiprazole | 0,0 | |
| - Fluphenazine decanoate | 0,7 | |
| - Pipothiazine palmitate | 0,7 | |
| Number of trials of LAI-AP for the LAI-AP group (n = 100) during 3-year follow-up (%) | – | |
| - 1 trial | 65,0 | |
| - 2 trials | 30,0 | |
| - 3 trials | 5,0 | |
| - 4 trials | 0 | |
| Number of trials of OAP for the OAP group (n = 275) during 3-year follow-up (%) | – | |
| - 1 trial | 70,5 | |
| - 2 trials | 23,6 | |
| - 3 trials | 5,1 | |
| - 4 trials | 0,7 | |
| Reasons for LAI-AP cessation (%) | – | |
| - Desire to see if medication is needed | 50,8 | |
| - Desire to stop LAI-AP but accepts OAP | 28,8 | |
| - Adverse effects | 10,2 | |
| - No efficacy/switch to clozapine | 10,2 | |
| Proportion of LAI-AP group receiving LAI-AP and OAP concomitantly (%) | 13,0 |
aIncluding lost to follow-up (23,6% at 12 months, 31,6% at 24 months and 41,5% at 36 months.